DURECT Corporation Announces Upcoming Conference Presentation
DURECT Corporation (NASDAQ: DRRX) is excited to share that James E. Brown, the President and Chief Executive Officer, will represent the company at the prestigious Oppenheimer 35th Annual Healthcare Life Sciences Conference. This event is all set to take place virtually on February 11-12.
Presentation Details You Should Know
This is an important opportunity for DURECT to share their cutting-edge research and innovations with the world. The presentation is scheduled for February 11 from 2:00 PM to 2:30 PM ET, which will be part of Track 5 of the conference. This slot is crucial as it will allow investors and stakeholders to gain insights into DURECT’s ongoing projects and future directions.
Engagement with Investors
In addition to the presentation, DURECT management values the chance to engage in one-on-one meetings with investors during the conference. This interaction will provide a platform to discuss potential opportunities, field inquiries, and share the company’s vision for the future.
About DURECT Corporation
DURECT is at the forefront of innovation as a late-stage biopharmaceutical company dedicated to the advancement of epigenetic therapies. These therapies specifically target dysregulated DNA methylation, a critical area in treating serious and life-threatening conditions like acute organ injury. One of DURECT's most promising drug candidates is Larsucosterol, which actively binds to and inhibits DNA methyltransferases. These enzymes are often elevated in patients with alcohol-associated hepatitis (AH), making Larsucosterol a key player in DURECT's pursuit of effective treatments.
Key Initiatives and Developments
Larsucosterol is currently in clinical development aimed at treating AH, and it has gained recognition from the FDA with both Fast Track and Breakthrough Therapy designations. Moreover, DURECT is also investigating its potential use in addressing metabolic dysfunction-associated steatohepatitis (MASH).
Besides Larsucosterol, DURECT is proud to have POSIMIR, an FDA-approved non-opioid analgesic solution designed for infiltration use. POSIMIR employs the innovative SABER platform technology, providing significant advantages in pain management without the risks associated with opioid medications.
Future Outlook and Shareholder Engagement
As DURECT looks to the future, the ongoing development of Larsucosterol is critical to the company’s growth trajectory. The chance to share these developments at the Oppenheimer conference reflects their commitment to transparency and communication with shareholders and potential investors. By fostering these relationships, DURECT aims to build a solid foundation for future success.
The firm is encouraged by the progress achieved so far and looks forward to sharing more insights and updates with investors. Those with an interest in DURECT's pursuits are encouraged to reach out to their Oppenheimer representative during the conference to make arrangements for meetings.
Frequently Asked Questions
What is the Oppenheimer Healthcare Life Sciences Conference?
The Oppenheimer Healthcare Life Sciences Conference is a key event where leading companies in the healthcare and life sciences sectors present their latest research and developments to investors.
When is DURECT's presentation at the conference?
DURECT's presentation is scheduled for February 11 from 2:00 PM to 2:30 PM ET.
What is Larsucosterol?
Larsucosterol is DURECT's lead drug candidate, which targets dysregulated DNA methyltransferases associated with alcohol-associated hepatitis and other serious conditions.
How is POSIMIR used in pain management?
POSIMIR is a non-opioid solution designed for infiltration use that helps manage pain without the associated risks of opioids.
How can I contact DURECT for more information?
For more insights, interested parties can visit DURECT's official website or reach out through their investor relations contacts.
